Background

Metachromatic Leukodystrophy (MLD) is a rare genetic disorder caused by mutations in the gene encoding arylsulfatase A (ARSA), a lysosomal enzyme. The resulting enzyme deficiency leads to the accumulation of sulfatide in the brain's white matter, progressively destroying myelin, the protective sheath around nerve fibers. This demyelination causes loss of motor and cognitive functions, ultimately leading to premature death. To combat this, hematopoietic stem cell gene therapy (HSC-GT) was developed, involving the collection of the patient's own hematopoietic stem cells and their re-infusion after transduction with a lentiviral vector carrying a normal ARSA gene. This therapy has demonstrated excellent efficacy in clinical trials, halting neurological progression and preserving cognitive function. However, the mechanism by which the transplanted hematopoietic stem cells cross the blood-brain barrier (BBB) and rescue surrounding, non-gene-corrected brain cells has remained largely unknown. Mouse studies have shown that therapeutic cells differentiate into microglia in the brain, secreting enzymes that are taken up by neighboring cells. However, it has not been directly demonstrated whether this occurs on a large scale in actual patients.

Key Findings

A research team led by Dr. Vasco Meneghini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) meticulously analyzed tissue samples from patients who underwent HSC-GT, revealing the mechanism of cross-correction. The analysis showed that the gene-corrected cells that infiltrated the patient's brain stably differentiated into a cell population similar to brain-resident myeloid cells, microglia. These cells produced normal ARSA enzyme at concentrations dozens of times higher than normal, based on the normal ARSA gene delivered by gene therapy, and continuously secreted it into the extracellular space. Remarkably, this released ARSA enzyme readily entered neighboring neurons and oligodendrocytes, which are essential for myelin regeneration and were previously deficient in the enzyme. This process occurs through mannose 6-phosphate receptors (M6PR) on the surface of recipient cells, which capture the secreted enzyme and internalize it. The internalized enzyme successfully cleared sulfatide within lysosomes, and as a result, the enzyme activity levels in the patients' cerebrospinal fluid stabilized to normal levels after treatment. The researchers demonstrated that even a small percentage of gene-corrected cells engrafting can completely correct the metabolic abnormalities in surrounding, non-gene-corrected brain cells, based on actual clinical data.

Significance and Implications

This study demonstrates that HSC-GT creates a molecular-ecological system that restores the entire tissue through cell-cell interactions, going beyond single-cell-level therapy. This provides strong biological evidence that the majority of brain cells that do not receive the therapeutic gene can also be rescued from enzyme deficiency. A novel therapeutic paradigm has been established, utilizing the brain's unique immune environment to use microglia as a platform for drug delivery. It suggests the possibility of establishing a self-sustaining enzyme factory network within the brain with a single hematopoietic stem cell transplantation. However, it remains unclear whether this cross-correction occurs in all areas of the brain. There may be some variation in the penetration depth and enzyme delivery rate of therapeutic cells depending on the region, such as the cerebral cortex or deep white matter. The research team is also focusing on studies to improve the initial cell engraftment rate in order to further enhance the efficiency of the enzyme delivery network.